Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 550-557

  Bryniarski, Krzysztof ^a   Szczepanik, Marian ^a   Ptak, Maria ^a   Zemelka, Magdalena ^a   Ptak, Włodzimierz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acrolein; Contact sensitivity; Cyclophosphamide; Cytokines; Macrophages; Nitrogen mustard; Oxygen radicals

Indexed keywords

2,4,6 TRINITROPHENYL; ACROLEIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRINITROPHENYL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL LABELING; CELL TRANSFER; CONTACT SENSITIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; IMMUNOGENICITY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE;

ACROLEIN; ANIMALS; CELLS, CULTURED; CYCLOPHOSPHAMIDE; DERMATITIS, CONTACT; IMMUNITY; INFLAMMATION MEDIATORS; MACROPHAGES, PERITONEAL; MALE; MECHLORETHAMINE; MICE; MICE, INBRED CBA; REACTIVE OXYGEN SPECIES;

EID: 67651165150     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70098-2     Document Type: Article

References (29)

1. Adams JD Jr, Klaidman LK: Acrolein-induced oxygen radical formation. Free Radic Biol Med, 1993, 2, 187-193.
2. Ben-Efraim S: Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targ, 2001, 2, 197-212.
3. Bracci L, Moschella F, Sestili P, La Rosa V, Valentini M, Canini I, Baccarini S et al.: Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res, 2007, 13, 644-653.
4. Britz JS, Askenase PW, Ptak W, Steinman RM, Gershon RK: Specialized antigen-presenting cells, splenic dendritic cells and peritoneal exudates cells induced by Mycobacteria activate effectoi cells that are resistant to suppression. J Exp Med, 1982, 155, 1344-1356.
5. + regulatory T-cells. J Immunol, 2006, 177, 6603-6612.
6. Bryniarski K, Maresz K, Szczepanik M, Ptak M, Ptak W: Modulation of macrophage activity by proteolytic enzymes. Different regulation of IL-6 and reactive oxygen intermediates (ROI's) synthesis as a possible homeostatic mechanism in the control of inflammation. Inflammation, 2003, 27, 333-340.
7. Bryniarski K, Ptak M, Ptak W: The in vivo and in vitro effects of alkylating agent, mechlorethamine, on IL-6 production in mice and the role of macrophages. Immunopharmacology, 1996, 34, 73-78.
8. Bryniarski K, Szczepanik M, Maresz K, Ptak M, Ptak W: Subpopulations of mouse testicular macrophages and their immunoregulatory function. Am J Reprod Immunol, 2004, 52, 27-35.
9. Colvin M, Padgett CA, Fenselau CA: Biological active metabolite of cyclophosphamide. Cancer Res, 1973, 33, 915-918.
10. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M: Some studies of active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol, 1974, 23, 115-129.
11. Couper NK, Blount DG, Riley EM: IL-10: the master regulator of immunity to infection. J Immunol 2008, 180, 5771-5777.
12. Ghaffar PRD, Sigel MM: Selective action of alkylating agents against cell participating in suppression of antibody responses. Int J Immunopharmacol, 1982, 4, 159-166.
13. - regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004, 34, 336-344.
14. Iwai T, Tomita Y, Okano S, Shimizu I, Yasunami Y, Kajiwara T, Yoshikai Y et al.: Regulatory roles of NKT cells in the induction and maintenance of cyclophosphamide-induced tolerance. J Immunol, 2006, 177, 8400-8409.
15. Kawabata TT, White KL Jr: Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein. Cancer Res, 1988, 48, 41-45.
16. Kehler JP, Biswal SS: The molecular effects of acrolein. Toxicol Sci, 2000, 57, 6-15.
17. Li LI, Hamilton RF Jr, Holian A: Effect of acrolein on human alveolar macrophage NF-κB activity. Am J Physiol Lung Cell Mol Physiol, 1999, 277, 550-557.
18. Majewska M, Zajac K. Dulak J, Szczepanik M: Heme oxygenase (HO-1) is involved in negative regulation of contact sensitivity reaction. Pharmacol Rep, 2008, 60, 933-940.
19. Marcinkiewicz J, Bryniarski K, Ptak W: Cyclophosphamide uncovers two separate macrophage subpopulations with opposite immunogenic potential and different patterns of monokine production. Cytokine, 1994, 6, 472-477.
20. Matar P, Rozados VR, Gervasoni SI, Scharovski OG: Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol, 2001,1, 307-319.
21. Ptak W, Bryniarski K, Nowak B, Szczepanik M, Ptak M: Heat aggregated immunoglobulins increase in vivo immunogenicity of mouse hapten (TNP) - derivatized macrophages by uppregulation of IL-12 secretion and expression of B7-1 and B7-2 costimulatory molecules. Scand J Immunol, 2000, 51, 479-484.
22. Ptak W, Klimek M, Bryniarski K, Ptak M, Majcher P: Macrophage function in alloxan diabetic mice: expression of adhesion molecules, generation of monokines and oxygen and NO radicals. Clin Exp Immunol, 1998, 114, 13-18.
23. Robinson JM, Ohira T, Badwey JA: Regulation of the NADPH-oxidase complex of phagocytic leukocytes. Recent insights from structural biology, molecular genetics and microscopy. Histochem Cell Biol, 2004, 122, 293-304.
24. Samaritani R, Corrado G, Vizza E, Sbiroli C: Cyclophosphamide "metronomic" chemotherapy for palliative treatment of young patient with advanced epithelial ovarian cancer. BMC Cancer, 2007, 7, 65-69.
25. Sladek NE: Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism. Cancer Res, 1972, 32, 1848-1854.
26. + T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol Ther 2007, 15, 1558-1563.
27. Szczepanik M, Bryniarski K, Pryjma J, Ptak W: Distinct populations of antigen-presenting macrophages are required for induction of effector and regulatory cells in contact sensitivity response in mice. J Leukoc Biol 1993, 53, 320-326.
28. Usui M, Sunshine GH, Dorf ME: A role of macrophage in suppressor cell induction. J Immunol, 1984, 132, 1728-1734.
29. Zimecki M, Arytm J, Ryng S, Obminska-Mrukowicz B: RM-11, an isoxazole derivative, accelerates restoration of immune function in mice treated with cyclophosphamide. Pharmacol Rep, 2008, 60, 183-189.